Identification and management of colitis and pneumonitis in IO plus chemotherapy metastatic NSCLC patients – a focus on KEYTRUDA
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Colitis and pneumonitis can be easily misdiagnosed as other conditions in lung cancer patients. This can be more complicated in combination IO plus chemotherapy patients. This video series shares real-world case studies of identifying and managing colitis and pneumonitis in mNSCLC patients treated with KEYTRUDA plus chemotherapy.
Licensed indications in mNSCLC
- KEYTRUDA as monotherapy is indicated for the first-line treatment of metastatic non-small cell lung carcinoma in adults whose tumours express PD-L1 with a ≥50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations
- KEYTRUDA, in combination with pemetrexed a`nd platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations
- KEYTRUDA, in combination with carboplatin and either paclitaxel or nab-paclitaxel, is indicated for the first-line treatment of metastatic squamous non-small cell lung carcinoma in adults
- KEYTRUDA as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung carcinoma in adults whose tumours express PD-L1 with a ≥1% TPS and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received targeted therapy before receiving KEYTRUDA
This module is CPD certified, offering a certificate upon completion.
You will need to be signed in to MSD Connect to download the certificate.
Introduction
Please use the tabs below to navigate through this case study, please note you must watch all videos in entirety to receive the CPD certificate.
We estimate the 5 videos and self-reflection will take roughly an hour to complete. Upon completion (if logged in) a CPD certificate will be sent to you automatically via email to download.
- Introduction
-
Identifying and managing
patients with immunotherapy
related colitis in those receiving
KEYTRUDA plus chemotherapy -
A real-world
case study:
Identifying and
managing a patient -
Assessing patients on
KEYTRUDA plus
chemotherapy with
breathing difficulties
for pneumonitis -
A real-world
case study:
Assessing a
patient
KEYLearning Feedback – NSCLC – Identification & management of colitis and pneumonitis in mNSCLC patients treated with KEYTRUDA + chemotherapy
Form for user to feedback on the module content, or recommendations for future modules
Related content
A guide to KEYTRUDA® (pembrolizumab) and how to manage immune-mediated adverse events
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
A guide to managing your metastatic non-small cell lung cancer patients on KEYTRUDA® (pembrolizumab) plus chemotherapy
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
References
- KEYTRUDA Summary of Product Characteristics.
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website.
